Karl Olof Borg, PhD
Dr. Borg is a former member of the Board of Alligator Bioscience. He holds a PhD in Pharmaceutical Sciences and was Adjunct Professor in Analytical Biochemistry at the University of Uppsala.
Previously Chief Scientific Officer and Vice President of Active Biotech AB, Dr. Borg has more than 25 years of experience from leading positions in the pharmaceutical industry including Astra,
Pharmacia and Ferring. Dr. Borg was in charge of the pre-clinical and clinical development of omeprazole (Losec).
Holbrook Kohrt, MD, PhD, Assistant Professor
Holbrook Kohrt, an Assistant Professor at Stanford Cancer Institute investigates novel therapeutic strategies to enhance anti-tumor immunity. Dr. Kohrt is trained in Internal Medicine at Stanford through the Clinical Investigator Pathway and has completed fellowship in Hematology and Oncology at Stanford with a research focus on preclinical models of novel immunomodulatory antibodies. Dr. Kohrt received his PhD in clinical trial design and tumor immunology from Stanford. His studies also include efforts to identify and develop novel vaccine strategies, as well as immunomodulatory antibodies targeting immune effector cells subsets. Dr. Kohrt’s trials, are currently being investigated in the US and three more countries.
Thomas Tötterman, MD, PhD, Professor
Professor Thomas Tötterman, Clinical Immunology Division, Department of Immunology, Genetics & Pathology, Uppsala University is an internationally recognized pioneer in the field of cancer immunotherapy. Alligator Bioscience has an extensive scientific collaboration with him and his group that has led to the development of the IMCAN (IMmunotherapy of CANcer) concept for local immunotherapy of cancer. Professor Tötterman is now involved in the pre-clinical development of Alligator Bioscience’s two pipeline projects within the IMCAN concept. Thomas Tötterman received his MD from the University of Helsinki, 1975 and his PhD from the same University 1978. He was appointed Professor/Senior Consultant in Clinical Immunology 1995 and was President for the Swedish Society of Gene and Cell Therapy (SSGCT) 2006-2010. Thomas Tötterman has been Initiator/Sponsor of two academic phase I/II trials, “first-in-man”, studies with immunomodulatory drug candidates. He has published more than 170 peer-reviewed scientific papers including several reviews.
Jeffrey Weber, MD, PhD, Professor
Professor Jeffrey Weber earned his Ph.D. in molecular cell biology from Rockefeller University (New York) in 1979 and received his M.D. from New York University in 1980. He completed his fellowship in Medical Oncology at the National Cancer Institute in Bethesda. Coming to Moffitt in 2007, Dr. Weber is a Senior Member, Director of the Donald A. Adam Comprehensive Melanoma Research Center, and Professor in the Department of Oncologic Sciences. Dr. Weber has published more than 100 articles in the top peer-reviewed journals in his field including New England Journal of Medicine and Nature Medicine. Dr. Weber currently sits on the scientific advisory boards of four cancer-related biotechnology companies. Clinically, he has held 10 investigator-initiated IND over the last decade, and has pursued cutting edge trials recently using gene modified dendritic cells, intranodal injection of plasmid-peptide priming and boosting and novel antibodies like CTLA-4 and PD-1 abrogating antibodies. He has been a pioneer in the clinical advancement of antibodies that induce autoimmunity as a surrogate for clinical benefit in cancer, and the management of the autoimmune side effects.